VEGFA and renal cell carcinoma: A prospective randomised double-blind three-arm phase II study of low (3 mg kg−1) and high (10 mg kg−1) dose bevacizumab given 2-weekly vs placebo in metastatic RCC was the first controlled study demonstrating clinical activity of an anti-VEGF approach in RCC (Yang et al, 2003).